Literature DB >> 11459787

Human follistatin-related protein: a structural homologue of follistatin with nuclear localization.

D V Tortoriello1, Y Sidis, D A Holtzman, W E Holmes, A L Schneyer.   

Abstract

Follistatin-related protein is a recently discovered glycoprotein that is highly homologous in both primary sequence and exon/intron domain structure to the activin-binding protein, follistatin. We explored their potential for functional redundancy by investigating the relative affinities and kinetics of their interactions with activin, bone morphogenic protein-6, and bone morphogenic protein-7 and by exploring their expression and distribution in human tissues and cells. Follistatin and follistatin-related protein mRNA were ubiquitous by Northern analyses, although their sites of peak distribution differed, with follistatin-related protein and follistatin predominating in the placenta and ovary, respectively. Follistatin-related protein, like follistatin, preferentially bound activin with high affinity and in an essentially irreversible fashion. Although follistatin-related protein, like follistatin, possesses a signal sequence and no known nuclear localization signals, its secretion was undetectable in most cell lines by RIA. Intriguingly, follistatin-related protein was identified as a nuclear protein in human granulosa cells and all human cell lines tested. Furthermore, Western analyses of CHO cells transfected with human follistatin-related protein revealed this protein to reside within the insoluble nuclear protein fraction. We conclude that despite its remarkably high level of similarity to follistatin with regard to structure and activin binding kinetics, follistatin-related protein is a nuclear as well as a secretory protein that may perform distinct intracellular actions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459787     DOI: 10.1210/endo.142.8.8319

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  48 in total

1.  Soluble repulsive guidance molecule c/hemojuvelin is a broad spectrum bone morphogenetic protein (BMP) antagonist and inhibits both BMP2- and BMP6-mediated signaling and gene expression.

Authors:  Mahta Nili; Ujwal Shinde; Peter Rotwein
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.

Authors:  Abir Mukherjee; Yisrael Sidis; Amy Mahan; Michael J Raher; Yin Xia; Evan D Rosen; Kenneth D Bloch; Melissa K Thomas; Alan L Schneyer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

3.  Follistatin-like 3 is a mediator of exercise-driven bone formation and strengthening.

Authors:  J Nam; P Perera; R Gordon; Y H Jeong; A D Blazek; D G Kim; B C Tee; Z Sun; T D Eubank; Y Zhao; B Lablebecioglu; S Liu; A Litsky; N L Weisleder; B S Lee; T Butterfield; A L Schneyer; S Agarwal
Journal:  Bone       Date:  2015-04-30       Impact factor: 4.398

Review 4.  Physical activity and its mechanistic effects on prostate cancer.

Authors:  A Wekesa; M Harrison; R W Watson
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-03-24       Impact factor: 5.554

5.  Human placenta and fetal membranes express follistatin-related gene mRNA and protein.

Authors:  P Ciarmela; P Florio; P Toti; A Franchini; V Maguer-Satta; C Ginanneschi; E Ottaviani; F Petraglia
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

6.  Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice.

Authors:  Nathan A Ungerleider; Lara M Bonomi; Melissa L Brown; Alan L Schneyer
Journal:  Endocrinology       Date:  2013-03-26       Impact factor: 4.736

7.  Hypoxia enhances the expression of follistatin-like 3 in term human trophoblasts.

Authors:  T Biron-Shental; W T Schaiff; E Rimon; T L Shim; D M Nelson; Y Sadovsky
Journal:  Placenta       Date:  2007-10-23       Impact factor: 3.481

8.  Agrin binds BMP2, BMP4 and TGFbeta1.

Authors:  László Bányai; Peter Sonderegger; László Patthy
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

Review 9.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  First-trimester follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus.

Authors:  Ravi Thadhani; Camille E Powe; May Lee Tjoa; Eliyahu Khankin; Jun Ye; Jeffrey Ecker; Alan Schneyer; S Ananth Karumanchi
Journal:  Diabetes Care       Date:  2009-12-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.